MDACC Study No:2012-0507 ( NCT No: NCT01720225)
Title:Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 3 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease
Principal Investigator:Elias Jabbour
Treatment Agent:Azacitidine; Decitabine
Study Status:Open
Study Description:The goal of this clinical research study is to compare how two different drugs,
decitabine and azacitidine, when given on a shorter than standard dosing
schedule can help to control MDS. The safety of the drugs will also be studied.

Decitabine is designed to damage the DNA (the genetic material) of cells, which
may cause cancer cells to die.

Azacitidine is designed to block certain proteins in cancer cells whose job is
to stop the function of the tumor-fighting proteins. By blocking the "bad"
proteins, the tumor-fighting genes may be able to work better. This could
cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Azacitidine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults